{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:57:03Z","timestamp":1765976223802,"version":"3.48.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian Pediatr"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13312-025-00206-2","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T06:52:54Z","timestamp":1759906374000},"page":"26-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of Hypertension During Induction Therapy in Children with Acute Lymphoblastic Leukemia"],"prefix":"10.1007","volume":"63","author":[{"given":"Yamini","family":"Karanam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita","family":"Trehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1009-7649","authenticated-orcid":false,"given":"Deepak","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"206_CR1","first-page":"83","volume":"64","author":"E Ward","year":"2014","unstructured":"Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64:83\u2013103.","journal-title":"CA Cancer J Clin"},{"key":"206_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IBPC.S242244","volume":"15","author":"L Murphy","year":"2022","unstructured":"Murphy L, Maloney K, Gore L, Blanchette E. Hypertension in pediatric acute lymphoblastic leukemia patients: prevalence, impact, and management strategies. Integr Blood Press Control. 2022;15:1\u201310.","journal-title":"Integr Blood Press Control"},{"key":"206_CR3","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s00467-021-05402-3","volume":"37","author":"R Kumar","year":"2022","unstructured":"Kumar R, Reed S, Stanek JR, Mahan JD. Defining kidney outcomes in children with acute lymphoblastic leukemia in the modern era. Pediatr Nephrol. 2022;37:2119\u201326.","journal-title":"Pediatr Nephrol"},{"key":"206_CR4","doi-asserted-by":"crossref","first-page":"e29837","DOI":"10.1002\/pbc.29837","volume":"69","author":"R Namjoshi","year":"2022","unstructured":"Namjoshi R, Lam CG, Hicks MJ, et al. Treatment-related toxicities associated with hospitalization during pediatric acute lymphoblastic leukemia induction therapy. Pediatr Blood Cancer. 2022;69:e29837.","journal-title":"Pediatr Blood Cancer"},{"key":"206_CR5","doi-asserted-by":"publisher","first-page":"S267","DOI":"10.1016\/S2152-2650(21)01650-5","volume":"21","author":"R Patel","year":"2021","unstructured":"Patel R, Jones S, Rahim M, Althouse S, Batra S. All-109: incidence, risk factors, and complications associated with hypertension during induction chemotherapy among adolescent and young adult patients with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2021;21:S267\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"206_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/MPH.0000000000000997","volume":"40","author":"I Bakk","year":"2018","unstructured":"Bakk I, Koch T, Stanek J, O\u2019Brien S, Reed S. Steroid-induced hypertension during induction chemotherapy for acute lymphoblastic leukemia in US children\u2019s hospitals. J Pediatr Hematol Oncol. 2018;40:27\u201330.","journal-title":"J Pediatr Hematol Oncol"},{"key":"206_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/FPC.0b013e3282fc5801","volume":"18","author":"LK Kamdem","year":"2008","unstructured":"Kamdem LK, Hamilton L, Cheng C, et al. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2008;18:507\u201314.","journal-title":"Pharmacogenet Genomics"},{"key":"206_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00467-007-0720-y","volume":"23","author":"CU Louis","year":"2008","unstructured":"Louis CU, Butani L. High blood pressure and hypertension in children with newly diagnosed acute leukemia and lymphoma. Pediatr Nephrol. 2008;23:603\u20139.","journal-title":"Pediatr Nephrol"},{"key":"206_CR9","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood.V112.11.3940.3940","volume":"112","author":"AS Freiberg","year":"2008","unstructured":"Freiberg AS, Kees-Folts D, Dyer AM, Taylor M. Incidence and risk factors for hypertension during induction chemotherapy for pediatric acute lymphoblastic leukemia. Blood. 2008;112:3940.","journal-title":"Blood"},{"key":"206_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3109\/08880019409141690","volume":"11","author":"SP Attard-Montalto","year":"1994","unstructured":"Attard-Montalto SP, Saha V, Ng YY, Kingston JE, Eden OB. High incidence of hypertension in children presenting with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1994;11:519\u201325.","journal-title":"Pediatr Hematol Oncol"},{"key":"206_CR11","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.18203\/2349-3291.ijcp20232875","volume":"10","author":"M Saha","year":"2023","unstructured":"Saha M, Jamal CY, Soma SA, Kaes MI. Evaluation of hematological and biochemical factors of hypertension during the induction chemotherapy for childhood acute lymphoblastic leukemia. Int J Contemp Pediatr. 2023;10:1491\u20138.","journal-title":"Int J Contemp Pediatr"},{"key":"206_CR12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s13312-018-1399-9","volume":"55","author":"P Malhotra","year":"2018","unstructured":"Malhotra P, Kapoor G, Jain S, Garg B. Incidence and risk factors for hypertension during childhood acute lymphoblastic leukemia therapy. Indian Pediatr. 2018;55:877\u20139.","journal-title":"Indian Pediatr"},{"key":"206_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.14238\/pi54.6.2014.372-6","volume":"54","author":"A Juliansen","year":"2014","unstructured":"Juliansen A, Andriastuti M, Pardede S, Sekartini R. Hypertension, high-dose corticosteroids, and renal infiltration in children with acute lymphoblastic leukemia. Paediatr Indones. 2014;54:372\u20136.","journal-title":"Paediatr Indones"},{"key":"206_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/01.mph.0000212990.64435.b9","volume":"28","author":"S Olgar","year":"2006","unstructured":"Olgar S, Yetgin S, Cetin M, Aras T. Can renal leukemic infiltration cause hypertension in children? J Pediatr Hematol Oncol. 2006;28:579\u201384.","journal-title":"J Pediatr Hematol Oncol"},{"key":"206_CR15","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1097\/MPH.0000000000001009","volume":"40","author":"JS Banerjee","year":"2018","unstructured":"Banerjee JS, Heyman M, Palom\u00e4ki M, et al. Posterior reversible encephalopathy syndrome: risk factors and impact on the outcome in children with acute lymphoblastic leukemia treated with Nordic protocols. J Pediatr Hematol Oncol. 2018;40:e13\u20138.","journal-title":"J Pediatr Hematol Oncol"},{"key":"206_CR16","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1080\/10428194.2019.1594210","volume":"60","author":"MGZ Ghali","year":"2019","unstructured":"Ghali MGZ, Davanzo J, Leo M, Rizk E. Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management. Leuk Lymphoma. 2019;60:2365\u201372.","journal-title":"Leuk Lymphoma"},{"key":"206_CR17","first-page":"1","volume":"4","author":"SJ Khan","year":"2018","unstructured":"Khan SJ, Arshad AA, Fayyaz MB, Mirza IUD. Posterior reversible encephalopathy syndrome in pediatric cancer: clinical and radiologic findings. J Glob Oncol. 2018;4:1\u20139.","journal-title":"J Glob Oncol"},{"issue":"6","key":"206_CR18","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3109\/10428191003754608","volume":"51","author":"R Parasole","year":"2010","unstructured":"Parasole R, Petruzziello F, Menna G, et al. Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution. Leuk Lymphoma. 2010;51(6):1063\u201371.","journal-title":"Leuk Lymphoma"},{"key":"206_CR19","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/HYP.0000000000000087","volume":"73","author":"P Muntner","year":"2019","unstructured":"Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension. 2019;73:e35-66.","journal-title":"Hypertension"},{"key":"206_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1542\/peds.114.S2.555","volume":"114","author":"National High Blood Pressure Education Program Working Group","year":"2004","unstructured":"National High Blood Pressure Education Program Working Group. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555\u201376.","journal-title":"Pediatrics"},{"key":"206_CR21","doi-asserted-by":"publisher","first-page":"e20171904","DOI":"10.1542\/peds.2017-1904","volume":"140","author":"JT Flynn","year":"2017","unstructured":"Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140:e20171904.","journal-title":"Pediatrics"},{"key":"206_CR22","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2017."},{"key":"206_CR23","unstructured":"Indian Childhood Collaborative Leukaemia Group. InPOG-ALL-15\u201301 (ICiCLe ALL-14) protocol, Version 3.0. New Delhi: Indian Pediatric Oncology Group; 2017."},{"key":"206_CR24","doi-asserted-by":"publisher","first-page":"e27594","DOI":"10.1002\/pbc.27594","volume":"66","author":"S Anastasopoulou","year":"2019","unstructured":"Anastasopoulou S, Eriksson MA, Heyman M, et al. Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: clinical characteristics, risk factors, course, and outcome of disease. Pediatr Blood Cancer. 2019;66:e27594.","journal-title":"Pediatr Blood Cancer"},{"key":"206_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4103\/ijc.IJC_422_19","volume":"58","author":"EA Rahiman","year":"2021","unstructured":"Rahiman EA, Rajendran A, Sankhyan N, et al. Acute neurological complications during acute lymphoblastic leukemia therapy: a single-center experience over 10 years. Indian J Cancer. 2021;58:545\u201352.","journal-title":"Indian J Cancer"}],"container-title":["Indian Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-025-00206-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13312-025-00206-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-025-00206-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:47:58Z","timestamp":1765975678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13312-025-00206-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1007\/s13312-025-00206-2","relation":{},"ISSN":["0019-6061","0974-7559"],"issn-type":[{"type":"print","value":"0019-6061"},{"type":"electronic","value":"0974-7559"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approved by the Institutional Ethics Committee, PGIMER, Chandigarh; Ref No: INT\/IEC\/2023\/SPL-1250 dated Oct 31, 2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}